title: Vaccination induced changes in pro-inflammatory cytokine levels as an early putative biomarker for cognitive improvement in a transgenic mouse model for Alzheimer disease.
abstract: Several pieces of experimental evidence suggest that administration of anti-β amyloid (Aβ) vaccines, passive anti-Aβ antibodies or anti-inflammatory drugs can reduce Aβ deposition as well as associated cognitive/behavioral deficits in an Alzheimer disease (AD) transgenic (Tg) mouse model and, as such, may have some efficacy in human AD patients as well. In the investigation reported here an Aβ 1-42 peptide vaccine was administered to 16-month old APP+PS1 transgenic (Tg) mice in which Aβ deposition, cognitive memory deficits as well as levels of several pro-inflammatory cytokines were measured in response to the vaccination regimen. After vaccination, the anti-Aβ 1-42 antibody-producing mice demonstrated a significant reduction in the sera levels of 4 pro-inflammatory cytokines (TNF-α, IL-6, IL-1 α, and IL-12). Importantly, reductions in the cytokine levels of TNF-α and IL-6 were correlated with cognitive/behavioral improvement in the Tg mice. However, no differences in cerebral Aβ deposition in these mice were noted among the different control and experimental groups, i.e., Aβ 1-42 peptide vaccinated, control peptide vaccinated, or non-vaccinated mice. However, decreased levels of pro-inflammatory cytokines as well as improved cognitive performance were noted in mice vaccinated with the control peptide as well as those immunized with the Aβ 1-42 peptide. These findings suggest that reduction in pro-inflammatory cytokine levels in these mice may be utilized as an early biomarker for vaccination/treatment induced amelioration of cognitive deficits and are independent of Aβ deposition and, interestingly, antigen specific Aβ 1-42 vaccination. Since cytokine changes are typically related to T cell activation, the results imply that T cell regulation may have an important role in vaccination or other immunotherapeutic strategies in an AD mouse model and potentially in AD patients. Overall, these cytokine changes may serve as a predictive marker for AD development and progression as well as having potential therapeutic implications.
authors.affiliation: a Department of Pharmacuetical Sciences College of Pharmacy; University of South Florida; Tampa, FL USA.
authors.forename: Xiaoyang
authors.initials: X
authors.lastname: Lin
authors.forename: Ge
authors.initials: G
authors.lastname: Bai
authors.forename: Linda
authors.initials: L
authors.lastname: Lin
authors.forename: Hengyi
authors.initials: H
authors.lastname: Wu
authors.forename: Jianfeng
authors.initials: J
authors.lastname: Cai
authors.forename: Kenneth E
authors.initials: KE
authors.lastname: Ugen
authors.forename: Chuanhai
authors.initials: C
authors.lastname: Cao
mesh_terms: D000544:Alzheimer Disease / Q000503:physiopathology* / Q000628:therapy*; D023582:Alzheimer Vaccines / Q000008:administration & dosage / Q000276:immunology*; D016229:Amyloid beta-Peptides / Q000008:administration & dosage / Q000276:immunology*; D000818:Animals; D015415:Biomarkers / Q000097:blood*; D016207:Cytokines / Q000097:blood*; D008569:Memory Disorders / Q000503:physiopathology*; D008822:Mice, Transgenic; D016896:Treatment Outcome
chemical_list: D023582:Alzheimer Vaccines; D016229:Amyloid beta-Peptides; D015415:Biomarkers; D016207:Cytokines
keywords: Alzheimer disease; amyloid-beta (Aβ); biomarker; cytokine; immunomodulation; inflammation